Haihong Yang

604 total citations
33 papers, 490 citations indexed

About

Haihong Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Haihong Yang has authored 33 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 8 papers in Surgery. Recurrent topics in Haihong Yang's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (14 papers) and Brain Metastases and Treatment (6 papers). Haihong Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (14 papers) and Brain Metastases and Treatment (6 papers). Haihong Yang collaborates with scholars based in China, United States and Netherlands. Haihong Yang's co-authors include Jianxing He, Qiuhua Deng, Yalei Zhang, Meiling Zhao, Wenju Lu, Ping He, Xin Xu, Qi Zhang, Jing Gao and Wei Wang and has published in prestigious journals such as Annals of Oncology, The American Journal of Surgical Pathology and Oncotarget.

In The Last Decade

Haihong Yang

30 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haihong Yang China 13 257 220 173 128 39 33 490
Bethany C. Prudner United States 12 190 0.7× 263 1.2× 168 1.0× 214 1.7× 35 0.9× 19 586
Sha Du China 11 75 0.3× 219 1.0× 96 0.6× 117 0.9× 22 0.6× 18 354
Katharina Wolff Germany 9 150 0.6× 218 1.0× 220 1.3× 86 0.7× 21 0.5× 15 481
Liming Gui China 9 238 0.9× 322 1.5× 114 0.7× 202 1.6× 35 0.9× 15 553
Jianzheng Zhu China 3 197 0.8× 222 1.0× 74 0.4× 157 1.2× 16 0.4× 6 376
Zicheng Sun China 10 95 0.4× 232 1.1× 144 0.8× 107 0.8× 23 0.6× 17 456
Ti‐Chun Chan Taiwan 14 97 0.4× 255 1.2× 103 0.6× 146 1.1× 14 0.4× 43 456
Kentaro Suina Japan 11 166 0.6× 198 0.9× 134 0.8× 143 1.1× 16 0.4× 20 375
Veronica Henderson United States 10 99 0.4× 307 1.4× 157 0.9× 182 1.4× 12 0.3× 15 479
Umar Raza China 14 88 0.3× 407 1.9× 153 0.9× 296 2.3× 45 1.2× 21 627

Countries citing papers authored by Haihong Yang

Since Specialization
Citations

This map shows the geographic impact of Haihong Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haihong Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haihong Yang more than expected).

Fields of papers citing papers by Haihong Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haihong Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haihong Yang. The network helps show where Haihong Yang may publish in the future.

Co-authorship network of co-authors of Haihong Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Haihong Yang. A scholar is included among the top collaborators of Haihong Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haihong Yang. Haihong Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xiong, Wei, Yali Liu, Haihong Yang, et al.. (2025). Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. International Immunopharmacology. 162. 115057–115057.
3.
Xiao, Dakai, et al.. (2021). High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer. OncoTargets and Therapy. Volume 14. 4809–4817. 8 indexed citations
4.
Qiu, Yuan, Liping Liu, Haihong Yang, et al.. (2021). Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer. Frontiers in Oncology. 10. 30 indexed citations
5.
Yang, Haihong, et al.. (2019). Predictive and prognostic value of phosphorylated c‑KIT and PDGFRA in advanced non‑small cell lung cancer harboring ALK fusion. Oncology Letters. 17(3). 3071–3076. 10 indexed citations
6.
Deng, Qiuhua, Yuan Qiu, Junmei Jia, et al.. (2019). Genetic alteration profile of EGFR-mutant resected IIB–IIIA stage NSCLC and correlation to clinical outcomes. Translational Lung Cancer Research. 8(6). 838–846. 5 indexed citations
7.
8.
Huang, Qing, Qiuhua Deng, Lei Jiang, et al.. (2016). Assessment of ALK gene fusions in lung cancer using the differential expression and exon integrity methods. Oncology Letters. 11(3). 1651–1656. 3 indexed citations
9.
10.
Yang, Haihong, Linbo Cai, Yalei Zhang, et al.. (2014). Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases. Journal of Molecular Diagnostics. 16(5). 558–563. 43 indexed citations
11.
Zhang, Yalei, Haihong Yang, Yuan Qiu, et al.. (2014). Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer. Medical Oncology. 31(3). 803–803. 5 indexed citations
12.
13.
Zhang, Yalei, Haihong Yang, Xinyun Yang, et al.. (2014). Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases. Molecular and Clinical Oncology. 2(3). 449–453. 3 indexed citations
14.
Zhou, Jeff X., Haihong Yang, Xin Gu, et al.. (2013). Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Annals of Oncology. 24(5). 1319–1325. 69 indexed citations
15.
16.
Liu, Jun, Yongping Lin, Haihong Yang, et al.. (2011). The expression of p33ING1, p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer. Tumor Biology. 32(6). 1113–1121. 28 indexed citations
17.
Guan, Yubao, Qingsi Zeng, Haihong Yang, et al.. (2011). Pulmonary alveolar proteinosis: Quantitative CT and pulmonary functional correlations. European Journal of Radiology. 81(9). 2430–2435. 7 indexed citations
18.
Yang, Haihong, Wei Wang, Yalei Zhang, et al.. (2011). The Role of NF-E2-Related Factor 2 in Predicting Chemoresistance and Prognosis in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 12(3). 166–171. 60 indexed citations
19.
Deng, Qiuhua, Haihong Yang, Xin Zhang, et al.. (2010). [Correlation between pre-treatment anemia and prognosis in non-small cell lung cancer patients].. PubMed. 13(7). 722–6. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bethany C. Prudner Breakdown of academic impact, for papers by Sha Du Breakdown of academic impact, for papers by Katharina Wolff Breakdown of academic impact, for papers by Liming Gui Breakdown of academic impact, for papers by Jianzheng Zhu Breakdown of academic impact, for papers by Zicheng Sun Breakdown of academic impact, for papers by Ti‐Chun Chan Breakdown of academic impact, for papers by Kentaro Suina Breakdown of academic impact, for papers by Veronica Henderson Breakdown of academic impact, for papers by Umar Raza
Rankless by CCL
2026